Natalie Grover, MD, will review some of the recent advances in the treatment of lymphoma, including the incorporation of novel targeted agents in the frontline treatment of diffuse large B cell lymphoma and Hodgkin lymphoma, the use of CAR-T cell therapy in second-line treatment in diffuse large B cell lymphoma, and recently approved drugs by the FDA for lymphoma.

This course contains twelve classes, each one focused on a different topic concerning cancer:

Taking a deeper dive into the most common oncologic emergencies facing oncology patients. We will discuss the clinical manifestations, diagnosis, treatment, and prevention of Neutropenic Fever, Tumor Lysis Syndrome, and Cord Compression. These topics are good refreshers for APPs practicing in primary care, urgent, emergency medicine, hematology/oncology, and inpatient medicine.

Patients undergoing treatment for cancer utilize many medications that have relevant drug-gene interactions. The use of pharmacogenomic testing can assist with drug selection, drug dosing, and the development of personalized medication monitoring plans. Amber Cipriani, PharmD, BCOP, will describe some common examples of drug-gene interactions relevant to oncology. She will also discuss current efforts to expand the use of pharmacogenomic testing into current clinical practice.